Compounded GLP-1 Treatment Advocacy Form

Make your voice heard—urge Congress and the FDA to preserve access to compounded GLP-1 treatments.

I am writing to express my concern about the potential loss of access to compounded GLP-1 treatments, which hundreds of thousands of Americans have found to be essential for managing their health.

Due to affordability and availability issues, patients have relied on compounded semaglutide through Mixx Health and Wellness as an alternative to the brand-name medications from Eli Lilly and Novo Nordisk. If the FDA moves forward with restricting compounded GLP-1s, patients will be faced with the difficult choice of either spending significantly more money on name-brand products or forgoing a treatment that has been life-changing.

Compounded GLP-1s are not just an alternative—they are essential medications for patients who rely on them to manage their health safely and effectively. Restricting access to compounded GLP-1s would undermine the health of patients who have no other viable options.

I ask you to consider the real, life-changing impact of these treatments. Please ensure that patients continue to have access to compounded GLP-1s as a critical part of health management. I hope that the administration listens to the voices of those who support and depend on this medication.

Thank you for your attention to this matter.

Fill this out to send your message:

Prefix

First Name

Last Name

Address

Zip Code

Phone

Agreement

I agree for Mixx Health and Wellness to send this message to the FDA and US Congressional offices on my behalf. I also agree to the Terms of Service and acknowledge the Privacy Policy. I understand that my first and last name will be published on a public FDA docket. Compounded semaglutide is not approved nor evaluated for safety, effectiveness, or quality by the FDA.

Compounded GLP-1 Treatment Advocacy Form

Make your voice heard—urge Congress and the FDA to preserve access to compounded GLP-1 treatments.

Let's get your appointment scheduled!